Yuzu | $35,000,000 | (Apr 7, 2026)
Moonbounce | $12,000,000 | (Apr 7, 2026)
Insight Health AI, Inc. | $11,000,000 | (Apr 7, 2026)
BenchSci
Canada
- Toronto, Ontario
- 24/01/2022
- Series C
- $63,000,000
BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. To achieve this, we're exponentially increasing the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence.
Backed by F-Prime, Gradient Ventures (Google’s AI fund), Inovia Capital, and TCV, our platform accelerates science at 16 of the top-20 pharmaceutical companies, and over 4,300 leading research centers worldwide.
We’re a remote-first company recognized for our impact and culture as a Deloitte Tech Fast 50TM, CIX Top 10 Growth, Great Place to Work®, and top-ranked organization on Glassdoor.
- Industry Software Development
- Website https://www.benchsci.com/
- LinkedIn https://www.linkedin.com/company/benchsci/about/
Related People
Tom Leung, MSc PhDFounder
Canada -
Toronto, Ontario
--BenchSci: Search By Evidence--
Researchers often look for evidence-of-use in literature before buying a new antibody or reagent. BenchSci aim to provide value for scientists, providing quick and easy access to evidence-of-use for different antibodies and reagents in peer-reviewed literature. Through BenchSci, scientists will be able to search antibodies or reagents by evidence and validations.
Ridge AI | $2,600,000 | (Apr 7, 2026)
NeuBird AI | $19,300,000 | (Apr 7, 2026)
Stipple Bio | $100,000,000 | (Apr 7, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
EnerVenue | $300,000,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)